2.Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. 3. Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT...
参考文献(滑动查看): [1] Prostate cancer-NCCN Guidelines Version 1.2023. [2] Prostate Cancer-NCCN Guidelines Version 4.2022. [3] Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and doceta...
[3] Prostate Cancer-NCCN Guidelines Version 2.2023. [4] de Bono JS, Mehra N, Scagliotti GV, et al. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. Lancet [5] Fizazi K, Foulon S, Carles J...
NCCNGuidelinesVersion4.2023 ComprehensiveTabinotCantars Cancer NCCN NetworkProstateCancerDncussian SYSTEMICTHERAPYFORMICRPC |·ContinueADTtomaintain| Metastaticlesion castratelevelsofsenum biopsy99gAdenocarcinoma999一 testosterone(50ng/dL)→SeePROS-15 Tumortosting ...
Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med 2019; 381:2506-2518. Changed footnote: Patients with disease progression on a given therapy should not repeat that therapy, with the exception of docetaxel, which can be given as a rechallenge after ...
参考文献[1]National Comprehensive Cancer Network. (NCCN) Clinical Practice Guidelines inOncology. Prostate Cancer, Version 2. 2020. [2]de Bono J, Mateo J, Fizazi K, et al. Olaparib for MetastaticCastration-Resistant Prostate Cancer [published online ahead of print, 2020 Apr28]. N Engl J Me...
NCCN Guidelines are widely recognized and used as the standard for clinical policy in oncology by clinicans and payors
NCCN Guidelines Version 4 2013 Prostate Cancer PROS 9 PROS E 2 of 3 Advanced disease Modified last bullet first paragraph Revised Secondary Hormonal additional systemic therapy forcastration recurrent prostate cancer Studies positive for metastatic disease asymptomatic secondary hormonal therapy changed ...
Florida) — "More rigorous" monitoring of active surveillance and "completely revamped" systemic therapy for metastatic disease are the big changes to the prostate cancer guidelines from the National Comprehensive Cancer Network (NCCN), said James Mohler, MD, chair of the NCCN prostate cancer panel...
Newer targeted options entered the NCCN Guidelines for metastatic urothelial cancer more than 1 year ago, “but they may still be new in the minds of many,” she said. They include the following agents: Erdafitinib, the first biomarker-directed therapy to be approved in this setting ...